<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiotomsk</journal-id><journal-title-group><journal-title xml:lang="ru">Сибирский журнал клинической и экспериментальной медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Siberian Journal of Clinical and Experimental Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2713-2927</issn><issn pub-type="epub">2713-265X</issn><publisher><publisher-name>TSU publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29001/2073-8552-2019-34-3-97-102</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiotomsk-818</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Системное воспаление у больных артериальной гипертонией и ишемической болезнью сердца различных возрастных групп</article-title><trans-title-group xml:lang="en"><trans-title>Systemic inflammation in patients with hypertension and coronary artery disease in different age groups</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4810-4795</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Останина</surname><given-names>Ю. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Ostanina</surname><given-names>Yu. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, ассистент кафедры фармакологии, клинической фармакологии и доказательной медицины, </p><p>630091, Новосибирск, Красный пр., 52 </p></bio><bio xml:lang="en"><p>Cand. Sci. (Med.), Assistant Professor, Department of Pharmacology, Clinical Pharmacology and Evidence-Based Medicine,</p><p>52, Krasniy pr., Novosibirsk, 630091</p></bio><email xlink:type="simple">julia679@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4735-5178</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яхонтов</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Yakhontov</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, профессор кафедры фармакологии, клинической фармакологии и доказательной медицины,</p><p>630091, Новосибирск, Красный пр., 52 </p></bio><bio xml:lang="en"><p>Dr. Sci. (Med.), Professor, Department of Pharmacology, Clinical Pharmacology and Evidence-Based Medicine,</p><p>52, Krasniy pr., Novosibirsk, 630091</p></bio><email xlink:type="simple">mich99@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8381-1911</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Звонкова</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zvonkova</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант кафедры терапии, гематологии и трансфузиологии ФПК и ППВ,</p><p>630091, Новосибирск, Красный пр., 52 </p></bio><bio xml:lang="en"><p>Post-Graduate Student, Department of Therapy, Hematology and Transfusiology, FPK and PPV,</p><p>52, Krasniy pr., Novosibirsk, 630091</p></bio><email xlink:type="simple">nastya.zvonckova@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2757-6988</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Журавлева</surname><given-names>И. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhuravleva</surname><given-names>I. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>ассистент кафедры фармакологии, клинической фармакологии и доказательной медицины,</p><p>630091, Новосибирск, Красный пр., 52 </p></bio><bio xml:lang="en"><p>Assistant Professor, Department of Pharmacology, Clinical Pharmacology and Evidence-Based Medicine,</p><p>52, Krasniy pr., Novosibirsk, 630091</p></bio><email xlink:type="simple">irina.zhuravleva19@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дуничева</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Dunicheva</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>главный врач,</p><p>630047, Новосибирск, ул. Залесского 6, к. 8</p></bio><bio xml:lang="en"><p>Chief Physician, </p><p>8, Zaleski str., 6, build. Novosibirsk, 630047</p></bio><email xlink:type="simple">cardio-nso@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5231-961X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яхонтова</surname><given-names>П. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Yakhontova</surname><given-names>P. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>заместитель главного врача по лечебным вопросам,</p><p>630047, Новосибирск, ул. Залесского 6, к. 8</p></bio><bio xml:lang="en"><p>Deputy Chief Physician for Treatment Issues,</p><p>8, Zaleski str., 6, build. Novosibirsk, 630047</p></bio><email xlink:type="simple">P_yakhont@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Новосибирский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Novosibirsk State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Новосибирский областной клинический кардиологический диспансер</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Novosibirsk Regional Clinical Cardiology Dispensary</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>02</day><month>11</month><year>2019</year></pub-date><volume>34</volume><issue>3</issue><fpage>97</fpage><lpage>102</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Останина Ю.О., Яхонтов Д.А., Звонкова А.В., Журавлева И.И., Дуничева О.В., Яхонтова П.К., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Останина Ю.О., Яхонтов Д.А., Звонкова А.В., Журавлева И.И., Дуничева О.В., Яхонтова П.К.</copyright-holder><copyright-holder xml:lang="en">Ostanina Y.O., Yakhontov D.A., Zvonkova A.V., Zhuravleva I.I., Dunicheva O.V., Yakhontova P.K.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.sibjcem.ru/jour/article/view/818">https://www.sibjcem.ru/jour/article/view/818</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования: определить и сопоставить уровень маркеров системного воспаления (С-реактивный белок – СРБ, цитокины) у больных артериальной гипертонией (АГ) и ишемической болезнью сердца (ИБС) различных возрастных групп.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследовании участвовали 106 больных АГ (мужчины) и стабильной стенокардией напряжения, в том числе 59 – молодого и среднего возраста (52 [46,5; 55] лет) – 1-я группа и 47 пожилых (64 [62; 67] лет; р &lt; 0,001) – 2-я группа. Критериями исключения были женский пол, сахарный диабет, инфаркт миокарда давностью менее 6 мес., онкологические и аутоиммунные заболевания, хронические заболевания в стадии обострения, острые инфекционные и психические заболевания. Уровень СРБ определялся методом иммуноферментного анализа (ИФА) с помощью тест-системы ELISA (Biomerica), США. Определение содержания цитокинов проводилось в сыворотке крови методом ИФА с помощью тест-систем Вектор Бест (Россия). Статистическую обработку результатов осуществляли в свободно распространяемой программе Rstudio. Различие считалось статистически значимым при p &lt; 0,05.</p></sec><sec><title>Результаты</title><p>Результаты. Уровень СРБ и частота повышения его значений у больных АГ и ИБС в различных возрастных группах статистически значимо не различались и были в пределах референсных значений, что, вероятно, связано с приемом препаратов, обладающих системным противовоспалительным эффектом. Повышение ИЛ-6 чаще встречалось в группе молодого и среднего возраста (47, 85,5%/27, 62,8%, р = 0,032). Повышение уровня ИЛ-8 также чаще определялось у пациентов молодого и среднего возраста (10,7 [7,3; 19]/5,9 [4,35; 9,3], р = 0,006).</p></sec><sec><title>Заключение</title><p>Заключение. Полученные данные указывают как на повышенный риск острых сердечно-сосудистых событий и более агрессивное течение ИБС у пациентов с АГ молодого и среднего возраста, так и на возможный запуск процесса раннего сосудистого старения у этой группы больных. </p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To determine and compare the levels of systemic inflammation markers (C-reactive protein (CRP) and cytokines) in different age groups of hypertensive patients with coronary artery disease (CAD).</p></sec><sec><title>Material and Methods</title><p>Material and Methods. The study involved 106 patients (men) with hypertension and stable angina. Group 1 included 59 young and middle-aged individuals (52 [46.5; 55] years); group 2 comprised 47 elderly individuals (64 [62; 67] years; p &lt; 0.001). The exclusion criteria were female gender, diabetes, myocardial infarction in the previous six months, exacerbation phase of chronic diseases, acute infectious and mental illnesses. The CRP levels were determined by ELISA test system (Biomerica, USA). The serum cytokine levels were assessed using Vector Best test systems (Russia). Statistical processing of data was performed in the freely distributed Rstudio software. The differences were considered statistically significant if p &lt; 0.05.</p></sec><sec><title>Results</title><p>Results. The levels of CRP and the frequencies of its increase did not significantly differ in patients with hypertension and CAD in different age groups and were within the reference values, which was, probably, due to the use of drugs with systemic antiinflammatory effect. Increases in the IL-6 levels were more common in group of young and middle-aged men (47, 85.5%/27, 62.8%, p = 0.032). Increases in the IL-8 levels were also more frequently detected in young and middle-aged patients (10.7 [7.3; 19]/5.9 [4.35; 9.3], p = 0.006).</p></sec><sec><title>Conclusion</title><p>Conclusion. Obtained data suggest both an increased risk of acute cardiovascular events and more aggressive course of CAD in young and middle-aged patients with hypertension, and a possible onset of early vascular aging in this group. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертония</kwd><kwd>ишемическая болезнь сердца</kwd><kwd>С-реактивный белок</kwd><kwd>интерлейкины 6</kwd><kwd>8</kwd><kwd>синдром раннего сосудистого старения</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hypertension</kwd><kwd>coronary artery disease</kwd><kwd>C-reactive protein</kwd><kwd>interleukin-6</kwd><kwd>interleukin-8</kwd><kwd>early vascular aging</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Байдина Т.В., Данилова М.В., Фрейд Г.Г. Цитокиновый статус больных с атеросклеротическим поражением сонных артерий. Цитокины и воспаление. 2013;12(3):100–103.</mixed-citation><mixed-citation xml:lang="en">Baydina T.V., Danilova M.V., Freud G.G. Cytokine status of patients with atherosclerotic lesions of the carotid arteries. Cytokines and Inflammation. 2013;12(3):100–103 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Павлунина Т.О., Шувалова Ю.А., Каминная В.И. Ассоциация уровней интерлейкина-6 и холестерина липопротеинов высокой плотности с тяжестью атеросклеротического поражения коронарных артерий. Атеросклероз и дислипидемии. 2013;4:57–62.</mixed-citation><mixed-citation xml:lang="en">Pavlunina T.O., Shuvalov Yu.A., Kaminnaya V.I. The association of interleukin-6 and high-density lipoprotein cholesterol levels with the severity of atherosclerotic lesions of the coronary arteries. The Journal of Atherosclerosis and Dyslipidemias. 2013;4:57–62 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Карпова А.М., Рвачева А.В., Шогенова М.Х., Жетишева Р.А., Масенко В.П., Наумов В.Г. Современные представления об иммуновоспалительных механизмах атеросклероза. Атеросклероз и дислипидемии. 2014;1:25–30.</mixed-citation><mixed-citation xml:lang="en">Karpova A.M., Rvacheva A.V., Shogenova M.Kh., Zhetisheva R.A., Masenko V.P., Naumov V.G. Modern ideas about the immune-inflammatory mechanisms of atherosclerosis. The Journal of Atherosclerosis and Dyslipidemias. 2014;1:25–30 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Granér M., Varpula M., Kahri J., Salonen R.M., Nyyssönen K., Nieminen M.S. et al. Association of carotid intima media thickness with angiographic severity and extent of coronary artery disease. Am. J. Cardiol. 2006;97:624–629. DOI: 10.1016/j.amjcard.2005.09.098.</mixed-citation><mixed-citation xml:lang="en">Granér M., Varpula M., Kahri J., Salonen R.M., Nyyssönen K., Nieminen M.S. et al. Association of carotid intima media thickness with angiographic severity and extent of coronary artery disease. Am. J. Cardiol. 2006;97:624–629. DOI: 10.1016/j.amjcard.2005.09.098.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Qiaowen Li, Zhiliang Li, Xiaoyong Zhang, Yunjun Ruan, Jian Qiu. Evaluated plasma interleukin-18/interleukin-10 ratio is a risk factor for acute coronary syndromes in patients with stable angina pectoris. Cardiology Journal. 2014;(21)1:83–88.</mixed-citation><mixed-citation xml:lang="en">Qiaowen Li, Zhiliang Li, Xiaoyong Zhang, Yunjun Ruan, Jian Qiu. Evaluated plasma interleukin-18/interleukin-10 ratio is a risk factor for acute coronary syndromes in patients with stable angina pectoris. Cardiology Journal. 2014;(21)1:83–88.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hu H., Cui H., Han W., Ye L., Qiu W., Yang H. et al. A cutoff point for arterial stiffness using the cardio-ankle vascular index based on carotid arteriosclerosis. Hypertens. Res. 2013;36(4):334–341. DOI: 10.1038/hr.2012.192.</mixed-citation><mixed-citation xml:lang="en">Hu H., Cui H., Han W., Ye L., Qiu W., Yang H. et al. A cutoff point for arterial stiffness using the cardio-ankle vascular index based on carotid arteriosclerosis. Hypertens. Res. 2013;36(4):334–341. DOI: 10.1038/hr.2012.192.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Early Vascular Aging (EVA). New directions in cardiovascular protection. Ed. Nilsson P., Olsen M., Laurent S. London: Academic Press; 2015:376.</mixed-citation><mixed-citation xml:lang="en">Early Vascular Aging (EVA). New directions in cardiovascular protection. Ed. Nilsson P., Olsen M., Laurent S. London: Academic Press; 2015:376.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Стражеско И.Д., Ткачева О.Н., Акашева Д.У., Дудинская Е.В., Агальцов М.В., Кругликова А.С. и др. Взаимосвязь компонентов метаболического синдрома с параметрами клеточного и сосудистого старения. Российский кардиологический журнал. 2014;6:30–34.</mixed-citation><mixed-citation xml:lang="en">Strazhesko I.D., Tkacheva O.N., Akasheva D.U., Dudinskaya E.V., Agaltsov M.V., Kruglikova A.S. et al. Interrelation of components of the metabolic syndrome with cellular and vascular parameters aging. Russian Journal of Cardiology. 2014;6:30–34 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Стратегия профилактики и контроля неинфекционных заболеваний и травматизма в Российской Федерации (проект). Профилактика заболеваний и укрепление здоровья. 2008;4:9–19.</mixed-citation><mixed-citation xml:lang="en">Strategy for the prevention and control of noncommunicable diseases and injuries in the Russian Federation (draft). Profilaktika zabolevanij i ukreplenie zdorov’ya. 2008;4:9–19 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Campisi J. Cellular senescence: putting the paradoxes in perspective. Curr. Opin. Genet. Dev. 2011;21:107–112. DOI: 10.1016/j.gde.2010.10.005.</mixed-citation><mixed-citation xml:lang="en">Campisi J. Cellular senescence: putting the paradoxes in perspective. Curr. Opin. Genet. Dev. 2011;21:107–112. DOI: 10.1016/j.gde.2010.10.005.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Erusalimsky J.D., Kurz D.J. Cellular senescence in vivo: its relevance in ageing and cardiovascular disease. Exp. Gerontol. 2005;40:634–642. DOI: 10.1016/j.exger.2005.04.010.</mixed-citation><mixed-citation xml:lang="en">Erusalimsky J.D., Kurz D.J. Cellular senescence in vivo: relevance in aging and cardiovascular disease. Exp. Gerontol. 2005;40:634–642. DOI: 10.1016/j.exger.2005.04.010.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ротарь О.П., Могучая Е.В., Костарева А.А., Конради А.О. Теломеры: реальная связь с сердечно-сосудистыми заболеваниями или чрезмерные надежды? Здравоохранение (Минск). 2014;2:51–58.</mixed-citation><mixed-citation xml:lang="en">Rotar O.P., Mighty E.V., Kostareva A.A., Konradi A.O. Telomeres: a real connection with cardiovascular diseases or excessive hopes? Healthcare (Minsk). 2014;2:51–58 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Appleby S., Pearson J.F., Aitchison A., Spittlehouse J.K., Joyce P.R., Kennedy M.A. Mean telomere length is not associated with current health status in a 50-year-old population sample. American Journal of Human Biology. 2017;29(1):462–470. DOI: 10.1002/ajhb.22906.</mixed-citation><mixed-citation xml:lang="en">Appleby S., Pearson J.F., Aitchison A., Spittlehouse J.K., Joyce P.R., Kennedy M.A. Mean telomere length is not associated with a 50-year-old population. American Journal of Human Biology. 2017;29(1):462 470. DOI: 10.1002/ajhb.22906.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Skvortsov D.A., Ezhova M.A., Lourie Y.E., Metelin A.V., Strazhesko I.D., Dudinskaya E.N. et al. Telomerase activity in peripheral blood mononuclear cells as a universal scale for quantitative measurement of telomerase activation on the example of liver diseases. Doklady Biochemistry and Biophysics. 2015;462:172–175. DOI: 10.1134/S1607672915030096.</mixed-citation><mixed-citation xml:lang="en">Skvortsov D.A., Ezhova M.A., Lourie Y.E., Metelin A.V., Strazhesko I.D., Dudinskaya E.N. et al. Telomerase activity in peripheral blood cells. Doklady Biochemistry and Biophysics. 2015;462:172 175. DOI: 10.1134/S1607672915030096.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Yeh J.K., Wang C.Y. Telomeres and Telomerase in Cardiovascular Diseases. Genes (Basel). 2016;7(9):pii: E58. DOI: 10.3390/genes7090058. 16. Диагностика и лечение хронической ишемической болезни сердца [Электронный ресурс]. Клинические рекомендации. 2013. URL: http://webmed.irkutsk.ru/doc/pdf/fedcad.pdf.</mixed-citation><mixed-citation xml:lang="en">Yeh J.K., Wang C.Y. Telomeres and telomerase in cardiovascular diseases. Genes (Basel). 2016;7(9):pii: E58. DOI: 10.3390/genes7090058.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Rakhit R.D., Seiler C., Wustmann K., Zbinden S., Windecker S., Meier B. et al. Tumor necrosis factor and interleukin- release during primary percutaneous coronary intervention for acute myocardial infarction is related to coronary collateral flow. Coron. Artery Dis. 2005;16(3):147–152.</mixed-citation><mixed-citation xml:lang="en">Diagnosis and treatment of chronic ischemic heart disease [Electronic resource]. Clinical guidelines. 2013 (In Russ.). URL: http://webmed.irkutsk.ru/doc/pdf/fedcad.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Каштанова Е.В., Полонская Я.В., Кургузов А.В. Воспалительные биомаркеры коронарного атеросклероза. Молекулярная медицина. 2015;5:62–64.</mixed-citation><mixed-citation xml:lang="en">Rakhit R.D., Seiler C., Wustmann K., Zbinden S., Windecker S., Meier B. et al. Tumor necrosis factor and interleukin-release during primary percutaneous coronary collateral flow. Coron. Artery Dis. 2005;16(3):147–152.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Иванушко Л.А., Крыжановский С.П., Киваева И.Ф. Коррекция цитокинового статуса полисахаридами морской бурой водоросли Fucus evanescens у пациентов с ишемической болезнью сердца и дислипидемией. Цитокины и воспаление. 2015;14(10):80–84.</mixed-citation><mixed-citation xml:lang="en">Kashtanova E.V., Polonskaya Ya.V., Kurguzov A.V. Inflammatory biomarkers of coronary atherosclerosis. Molecular medicine. 2015;5:62–64 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Пигаревский П.В., Мальцев С.В., Снегова В.А. Прогрессирующие атеросклеротические повреждения у человека. Морфологические и иммуновоспалительные аспекты. Цитокины и воспаление. 2013;12(1):5–12.</mixed-citation><mixed-citation xml:lang="en">Ivanushko L.A., Kryzhanovsky S.P., Kivaeva I.F. Correction of the cytokine status of Fucus evanescens sea brown alga polysaccharides in patients with ischemic heart disease and dyslipidemia. Cytokines and Inflammation. 2015;14(10):80–84 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Pigarevsky P.V., Maltsev S.V., Snegova V.A. Progressive atherosclerotic lesions in humans. Morphological and immunoinflammatory aspects. Cytokines and Inflammation. 2013;12(1):5–12 (In Russ.).</mixed-citation><mixed-citation xml:lang="en">Pigarevsky P.V., Maltsev S.V., Snegova V.A. Progressive atherosclerotic lesions in humans. Morphological and immunoinflammatory aspects. Cytokines and Inflammation. 2013;12(1):5–12 (In Russ.).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
